Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för SB-202190. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2013-12-25

Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia.

Yang S, Zhou G, Liu H, Zhang B, Li J, Cui R, Du Y.

Biomed Res Int · research-article; journal article · DOI 10.1155/2013/215798

Bibliografisk träff 2012-09-17

Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.

Grossi V, Liuzzi M, Murzilli S, Martelli N, Napoli A, Ingravallo G, Del Rio A, Simone C.

Cancer Biol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.4161/cbt.22254

Bibliografisk träff 2012-01-12

Calpains mediate integrin attachment complex maintenance of adult muscle in Caenorhabditis elegans.

Etheridge T, Oczypok EA, Lehmann S, Fields BD, Shephard F, Jacobson LA, Szewczyk NJ.

PLoS Genet · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pgen.1002471

Bibliografisk träff 2011-08-10

SB202190-induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition.

Menon MB, Kotlyarov A, Gaestel M.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0023054

Bibliografisk träff 2008-11-07

The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells.

Hirosawa M, Nakahara M, Otosaka R, Imoto A, Okazaki T, Takahashi S.

Leuk Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2008.09.028

Bibliografisk träff 2005-09-23

Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats.

Prakash J, Saluja V, Visser J, Moolenaar F, Meijer DK, Poelstra K, Kok RJ.

J Chromatogr B Analyt Technol Biomed Life Sci · validation study; journal article · DOI 10.1016/j.jchromb.2005.09.005

Bibliografisk träff 2000-10-01

A selective inhibitor of p38 MAP kinase, SB202190, induced apoptotic cell death of a lipopolysaccharide-treated macrophage-like cell line, J774.1.

Karahashi H, Nagata K, Ishii K, Amano F.

Biochim Biophys Acta · research support, non-u.s. gov't; journal article · DOI 10.1016/s0925-4439(00)00045-4

Bibliografisk träff 1998-09-01

SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes.

Manthey CL, Wang SW, Kinney SD, Yao Z.

J Leukoc Biol · journal article · DOI 10.1002/jlb.64.3.409

Bibliografisk träff 1998-06-01

Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase.

Nemoto S, Xiang J, Huang S, Lin A.

J Biol Chem · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1074/jbc.273.26.16415